Febrile Neutropenia Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Febrile Neutropenia Treatment Market is segmented By Disease Severity (Simple Febrile Neutropenia, Complicated Febrile Neutropenia), By Treatment Type (Broad-Spectrum Empiric Antibiotic Therapy, Empirical Antifungal Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Report Overview

Global febrile neutropenia treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a high CAGR during the forecast period 2023-2030.

Febrile neutropenia, also known as neutropenic fever, is the presence of neutropenia accompanied by a fever. Basically, neutropenia refers to a decrease in the concentration of neutrophils in blood. Neutrophils are a type of white blood cell that helps fight infections as part of the immune system. 

Neutropenia is an absolute neutrophil count (ANC) of less than 1500 cells/mm3. The risk of infection and neutropenic fever increases dramatically with severe neutropenia, which is defined as an absolute neutrophil count (ANC) below 500 cells/mm3. A fever is defined as either a single oral temperature greater or equal to 101 degrees Fahrenheit (38.3 degrees Celsius) or a sustained temperature greater or equal to 100.4 degrees Fahrenheit (38.0 degrees Celsius) or higher for an hour or longer.

Market Scope

For More Insights Request Free Sample

Market Dynamics: Drivers

Increasing adoption of biosimilars 

The increasing adoption of biosimilars is expected to drive the market over the forecast period. The biosimilars are safe and effective treatment options for the treatment of febrile neutropenia. Biosimilars increase access to lifesaving medications at potentially lower costs. Recently, there are many biosimilars have been launched due to their increasing adoption.

For instance, on February 16, 2023, Fresenius Kabi, a global healthcare company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, launched its pegfilgrastim biosimilar, Stimufend (pegfilgrastim-fpgk), in the United States.

Moreover, the biosimilars used in the treatment of febrile neutropenia show better patient outcomes. Many companies are collaborating to develop biosimilars in a safe and effective way. For instance, on November 22, 2022, Amneal Pharmaceuticals, Inc. cleared the commercial launch of RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. RELEUKO is used to treat febrile neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences.

In addition, the pegfilgrastim biosimilars are most commonly using for febrile neutropenia treatment. Pegfilgrastim is a pegylated granulocyte colony-stimulating factor that is FDA-approved to decrease the risk of patients developing febrile neutropenia when receiving myelosuppressive chemotherapy regimens. 

For instance, on May 22, 2023, Coherus BioSciences, Inc. released the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA (pegfilgrastim-cbqv) is now available for commercial sale in the United States. UDENYCA is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Further, the increasing prevalence of febrile neutropenia, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel therapeutics are the factors expected to drive the market over the forecast period.

Restraints

Factors such as adverse effects associated with antibiotics and other drugs, the availability of alternative treatment options, high investment costs in R&D, patent expiration of the most preferred drugs and the high cost of the drugs are expected to hamper the market. 

Segmentation Analysis

The global febrile neutropenia treatment market is segmented based on disease severity, treatment type, distribution channel and region.

The broad-spectrum empiric antibiotic therapy segment accounted for approximately 56.3% of the febrile neutropenia treatment market share

The broad-spectrum empiric antibiotic therapy segment is expected to hold the largest market share over the forecast period. The broad-spectrum empiric antibiotic therapy includes various types of antibiotics such as beta-lactam antibiotics like a combination of piperacillin-tazobactam and vancomycin-carbapenems, aminoglycoside antibiotics like gentamicin, amikacin, glycopeptide antibiotics, cephalosporin antibiotics and others.

Moreover, antibiotics are considered as a first-line treatment for the febrile neutropenia. The usage of the broad spectrum antibiotics is known for reducing the mortality rate. For instance, according to the antimicrobe organization, the initiation of broad-spectrum antibiotics at the very onset of fever in neutropenic patients, decreased dramatically the mortality. This concept of empiric therapy is still one of the major elements of standard care for febrile neutropenia nowadays.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In addition, their wide adoption also increases the demand for broad-spectrum antibiotics. For instance, according to the National Institute Of Health (NIH), 2023, the most important determining factor of patient outcomes is the timing of administrating IV antibiotics. Early admission of antibiotics has been shown to reduce mortality and the hospital length of these patients.

Geographical Share

North America accounted for approximately 39.7% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing FDA approvals. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials leads to the launch of novel therapeutics and alternative treatment options.

Moreover, the FDA approvals for the treatment of febrile neutropenia are continuously increasing in the region, which is expected to drive the market in the region. For instance, on September 9, 2022, Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, cleared the U.S. Food and Drug Administration (FDA) approval for ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

Market Key Players

The major global players in the febrile neutropenia treatment market include Fresenius Kabi AG, Amgen Inc., Kyowa Kirin Co., Ltd., USV Private Limited, Apotex Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Coherus BioSciences, Inc. and Astellas Pharma Inc. among others. 

Key Developments

• For instance, on May 16, 2023, Amneal Pharmaceuticals, Inc. launched the FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat febrile neutropenia which is commonly experienced by patients undergoing chemotherapy. 
• On December 6, 2022, Kyowa Kirin Co., Ltd. launched the G-Lasta Subcutaneous Injection 3.6 mg BodyPod, which is an automated injection device of G-Lasta (KRN125, generic name, pegfilgrastim), long-acting Granulocyte Colony-Stimulating Factor is launched in Japan for decreasing the incidence of febrile neutropenia in patients receiving cancer chemotherapy.
• On April 28, 2020, Mylan N.V. and Biocon Ltd. launched the Fulphila, a biosimilar to Neulasta (pegfilgrastim). Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global febrile neutropenia treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global febrile neutropenia treatment market by temporarily disrupting many clinical trials, regulatory approvals and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global febrile neutropenia treatment market segmentation based on disease severity, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of febrile neutropenia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global febrile neutropenia treatment market report would provide approximately 61 tables, 56 figures, and 191 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies